Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Mar 09, 2022 6:10pm
103 Views
Post# 34501242

RE:RE:sh*ts and giggles ...

RE:RE:sh*ts and giggles ...
kentucky77 wrote: Agreed, I sense the time is right for EDNO to conveniantly off-load Palidin to the highest bidder and we both know who has the cash and the burning desire.  GLTU  


Ya - been wondering about that.
Goodman isn't willing to overpay ... but ...
there's roughly 69 drugs that are bringing in sales of $24M USD/qtr.
The new ENDO CEO knows that he's not going to fetch much on the open market for this portfolio and if sales start to decline, he's really going to have trouble offloading.

This just isn't an area where we wants to focus - the rest of his business in bleeding.

Strategic review should lead to something ... sooner than later ... you'd think.

<< Previous
Bullboard Posts
Next >>